# Hypofractionated Radiotherapy Plus GM-CSF, Pomalidomide and Glofitamab for Newly Diagnosed PCNS-DLBCL

> **NCT07749365** · PHASE2 · RECRUITING · sponsor: **The First Affiliated Hospital of Xiamen University** · enrollment: 53 (estimated)

## Conditions studied

- DLBCL - Diffuse Large B Cell Lymphoma
- PCNSL (Primary CNS Lymphoma)

## Interventions

- **DRUG:** hypofractionated radiotherapy plus GM-CSF, pomalidomide and glofitamab

## Key facts

- **NCT ID:** NCT07749365
- **Lead sponsor:** The First Affiliated Hospital of Xiamen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-25
- **Primary completion:** 2029-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 53 (ESTIMATED)
- **Last updated:** 2026-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07749365

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07749365, "Hypofractionated Radiotherapy Plus GM-CSF, Pomalidomide and Glofitamab for Newly Diagnosed PCNS-DLBCL". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07749365. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*